TD Cowen Raises Price Target for Guardant Health (GH) to $135
TD Cowen analyst Dan Brennan has increased the price target for Guardant Health (GH) from $130 to $135, maintaining a 'Buy' rating. This update reflects continued confidence in the company, a leader in liquid-based cancer tests. Other analysts have also recently raised their price targets for GH.
Leerink Partners Maintains Outperform Rating on Guardant Health (GH) | GH Stock News
Leerink Partners has reaffirmed its Outperform rating on Guardant Health (GH) and increased its price target from $170 to $180, following an announcement by analyst Puneet Souda. This decision comes amidst a series of varied analyst actions for GH, including new coverage and several price target adjustments from other firms. Guardant Health, a leader in liquid-based cancer tests, has an average target price of $126.24 from 23 analysts, implying a 22.44% upside, although GuruFocus estimates a one-year GF Value of $64.80.
Citigroup Raises Price Target for Guardant Health (GH) to $150
Citigroup has raised its price target for Guardant Health (GH) to $150, maintaining a "Buy" rating. This adjustment reflects a positive trend in analyst sentiment, with several recent price target upgrades for the company. Guardant Health specializes in liquid-based cancer tests and recently received FDA approval for its colorectal cancer screening tool, Shield.
TD Cowen Raises Price Target for Guardant Health (GH) to $135 | GH Stock News
TD Cowen has reaffirmed its 'Buy' rating for Guardant Health (GH), increasing the price target from $130 to $135, signaling continued confidence in the company. This follows several other analysts who have also raised price targets for Guardant Health, a leader in liquid-based cancer tests. Despite a positive Wall Street analyst consensus with an "Outperform" status and an average target price predicting a 21.36% upside, GuruFocus estimates a potential downside of 37.7% based on its GF Value fair value calculation.
Guardant Health (GH) Receives Maintained In-Line Rating with Rai
Evercore ISI Group analyst Daniel Markowitz has maintained an "In-Line" rating for Guardant Health (GH) and raised its price target from $105.00 to $110.00. This follows several other analyst adjustments, including an "Outperform" rating from Baird and "Buy" ratings from Guggenheim and Stifel with increased price targets. Guardant Health specializes in liquid-based cancer tests, and Wall Street analysts forecast an average target price of $126.24, implying an 18.67% upside, though GuruFocus estimates a potential downside based on its GF Value.
BTIG Research Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock
BTIG Research has raised its price target for Guardant Health (NASDAQ:GH) to $145, suggesting a 36.3% upside based on a "buy" rating. This optimistic forecast is supported by other analysts who have also increased their price targets, contributing to a consensus "Moderate Buy" rating for the stock. Despite strong Q4 revenue growth of 39% and a raised FY-2026 revenue guidance to $1.3 billion, the company reported a GAAP EPS miss, raising some profitability concerns among investors.
Guardant Health (NASDAQ:GH) Price Target Raised to $135.00
Canaccord Genuity Group has raised its price target for Guardant Health (NASDAQ:GH) from $125.00 to $135.00, maintaining a "buy" rating. This new target suggests a potential upside of 26.90% from the previous close. Other analysts also reiterated "buy" or "overweight" ratings, with an average price target of $108.59 across all analysts.
Guardant Health Reports Strong Q4 2025 Earnings with Significant Growth
Guardant Health reported a strong Q4 2025, with revenue increasing by 39% year-over-year to $281.3 million and full-year revenue reaching $982 million. The success of its Shield product, which generated $35 million in Q4 from 38,000 tests, significantly contributed to this growth and improved non-GAAP gross margins to 66%. The company also provided an optimistic 2026 outlook, forecasting revenue between $1.25 billion and $1.28 billion, reflecting confidence in continued oncology sector growth.
Guardant Health: Fourth Quarter Financial Overview
Guardant Health reported a net loss of $128.5 million, or $1 per share, for the fourth quarter, with an adjusted loss of 50 cents per share, missing analyst expectations. The cancer diagnostic services company generated $281.3 million in revenue for the quarter. For the full year, Guardant Health recorded a total loss of $416.3 million on revenue of $982 million, and projects future revenue between $1.25 billion and $1.28 billion.
Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales
Guardant Health (NASDAQ:GH) reported stronger-than-expected Q4 CY2025 revenue of $281.3 million, a 39.4% year-on-year increase, signaling robust demand for its liquid biopsy technology. While the company's full-year revenue guidance also surpassed analyst estimates, its non-GAAP loss per share of $0.50 missed consensus by 6.5%. Despite continued unprofitability, Guardant Health showed improvements in operating margin and reduced its EPS losses, with analysts expecting further improvements in the coming year.
Guardant Health earnings beat by $0.27, revenue topped estimates
Guardant Health (NASDAQ: GH) reported strong Q4 results, with EPS of $-0.50, significantly beating analyst estimates of $-0.77. The company's revenue also exceeded expectations, coming in at $281.3M against a consensus estimate of $268.98M. Guardant Health provided optimistic guidance, projecting FY 2026 revenue between $1.25B-$1.28B, surpassing the analyst consensus of $1.24B.
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Guardant Health reported strong financial results for Q4 and full year 2025, with total revenue increasing by 39% and 33% respectively. The company saw significant growth in its oncology and screening segments, particularly with its Shield screening tests. Guardant Health also provided an optimistic 2026 outlook, projecting total revenue growth between 27% and 30%.
Guardant Health: Q4 Earnings Snapshot
Guardant Health Inc. reported a Q4 loss of $128.5 million, or $1 per share, which was 50 cents per share when adjusted for certain costs, falling short of analyst expectations. The oncology testing services provider posted revenue of $281.3 million for the quarter and expects full-year revenue for 2026 to be between $1.25 billion and $1.28 billion. For the full year 2025, the company reported a loss of $416.3 million on revenue of $982 million.
Is FDA and Reimbursement Momentum Altering The Investment Case For Guardant Health (GH)?
Guardant Health (GH) recently reported strong quarterly revenue, exceeding analyst expectations, driven by progress in FDA submissions, reimbursement expansion, and margin improvement. While the company faces ongoing concerns about profitability and cash burn, these developments suggest positive operational momentum. The investment narrative hinges on liquid biopsy becoming a large cancer testing franchise, with regulatory and payer traction being key catalysts for future growth and reduced equity financing risk.
GSA Capital Partners LLP Increases Position in Guardant Health, Inc. $GH
GSA Capital Partners LLP significantly increased its stake in Guardant Health, Inc. (NASDAQ:GH) by 155.5% in the third quarter, now owning 21,982 shares valued at $1.37 million. Other institutional investors like PNC Financial Services Group Inc., Assetmark Inc., Caprock Group LLC, Navellier & Associates Inc., and Candriam S.C.A. also adjusted their positions in the company. Despite insider sales totaling over $45 million in the last ninety days, analysts maintain a "Moderate Buy" rating for Guardant Health with an average price target of $107.45.
Baird initiates Guardant Health stock coverage with outperform rating By Investing.com
Baird has initiated coverage on Guardant Health (NASDAQ:GH) with an "Outperform" rating and a price target of $120.00, suggesting a 14% upside from its current price. The firm highlighted Guardant Health's leadership in precision oncology and strong revenue growth, despite some reservations about future market share in colorectal cancer and competitive positioning. This positive outlook is supported by recent strong Q4 2025 results, FDA approval for Guardant360 CDx, and raised price targets from other analysts like Canaccord Genuity, Stifel, and Jefferies.
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow
Guardant Health (GH) is set to report its Q4 results tomorrow after market hours, with analysts expecting a 34.6% year-on-year revenue growth to $271.7 million and an adjusted loss of -$0.47 per share. The company has consistently beaten revenue estimates in the past two years. Despite general underperformance in the testing & diagnostics services segment, Guardant Health has an average analyst price target of $125 against its current share price of $107.54.
Guardant Health Q4 2025 Earnings Report Date & Analyst Forecasts - News and Statistics
Guardant Health is set to release its Q4 2025 financial results, with analysts projecting a 34.6% year-over-year revenue growth to $271.7 million and an adjusted loss of $0.47 per share. The company has a history of exceeding revenue expectations. The broader testing and diagnostics sector has recently underperformed, and Guardant Health's stock price has declined 7.5% over the last month.
Baird initiates Guardant Health stock coverage with outperform rating By Investing.com
Baird has initiated coverage on Guardant Health (NASDAQ:GH) with an Outperform rating and a $120 price target, suggesting a 14% upside from its current price. The firm cited Guardant Health's leadership in therapy selection for oncology and potential in pipeline initiatives, despite some reservations about its Shield product. This follows strong preliminary Q4 2025 results and FDA approval for Guardant360 CDx, leading other analysts to also reiterate or raise their price targets.
Baird initiates Guardant Health stock coverage with outperform rating
Baird has initiated coverage on Guardant Health Inc. (NASDAQ:GH) with an Outperform rating and a price target of $120.00, suggesting a 14% upside. The firm highlighted Guardant Health's leadership in precision oncology and strong revenue growth while acknowledging some reservations regarding future market share. This positive outlook follows several other analysts reiterating Buy ratings and raising price targets for the company.
A Look At Guardant Health (GH) Valuation After Insider Selling And New Cancer Testing Updates
Guardant Health (GH) is under scrutiny following insider selling and new clinical data for its cancer testing products. Despite strong longer-term stock performance, recent insider activity and a high price-to-sales ratio raise questions about its current valuation. The company is considered 16.3% undervalued by Simply Wall St's primary narrative, but risks like high cash burn and legal uncertainty persist.
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts
Guardant Health, Inc. (NASDAQ:GH) has received a "Moderate Buy" consensus rating from 23 analysts, with an average 12-month target price of $106.86. Several firms, including JPMorgan, BTIG, and Mizuho, have recently raised their price targets for the company. Despite insider sales totaling approximately $45.6 million over the last 90 days, institutional investors own 92.60% of the stock.
Guardant Health Grant Program Links Shield Test Access To Growth Story
Guardant Health has launched a Community Colorectal Cancer Screening Grant Program, offering free access to its FDA-approved Shield blood test in underserved communities. This initiative links public health goals with the company's strong stock performance, which has seen significant returns over the past three years. For investors, the program offers insight into the real-world adoption and patient reach of Guardant Health's product, though the company currently faces negative shareholders' equity and unprofitability.
Guardant Health Grant Program Links Shield Test Access To Growth Story
Guardant Health has launched a Community Colorectal Cancer Screening Grant Program to provide free access to its FDA-approved Shield blood test, targeting underserved communities. This initiative, coinciding with Colorectal Cancer Awareness Month, could offer valuable real-world data on test adoption for investors. Despite strong past stock performance, the company faces risks such as negative shareholder equity and unprofitability, making the program's long-term impact on its financial narrative a key consideration.
Analyzing Profit Zones For Walmart, Quanta Services And Guardant Health Ahead Of Earnings
In this "Earnings Cheat Sheet" segment from Investor's Business Daily, Alexis Garcia and Ed Carson provide a detailed preview of the upcoming earnings reports for three major companies: Walmart, Guardant Health, and Quanta Services. The discussion focuses on analyzing the "profit zones" for each of these companies to give investors insights ahead of their financial disclosures. This segment is part of IBD's broader coverage of earnings season and market analysis.
Community groups offered up to 100 free colon cancer blood tests for March events
Guardant Health has launched a Community Colorectal Cancer Screening Grant Program to provide up to 100 free Shield blood tests to selected organizations for community screening events and educational outreach during Colorectal Cancer Awareness Month in March. The program aims to increase access to screening, particularly in underserved communities, for individuals aged 45 and older at average risk. Applications for the grant are due by February 17, 2026, with approvals announced by February 20, 2026.
GoFundMe for James Van Der Beek’s family surpasses $1.5M in less than 24 hours
A GoFundMe campaign for the family of actor James Van Der Beek has raised over $1.5 million in less than 24 hours following his death. Van Der Beek, 48, died from colorectal cancer, leaving behind his wife and six children in "significant financial strain." The largest donation, $25,000, came from Guardant Health, a company for which Van Der Beek was a brand ambassador, and the funds will help cover living expenses, bills, and education costs for his children.
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open
Guardant Health has initiated a Community Colorectal Cancer Screening Grant Program to enhance access to screening during CRC Awareness Month in March. The company will provide up to 100 Shield blood tests at no cost to selected patient advocacy, non-profit, and public health organizations to support community screening events and educational outreach. Applications are currently open until February 17, 2026, for organizations looking to increase screening participation, especially in underscreened communities.
Guardant Health Shares Slide as Principal Cuts Stake and Insiders Sell
Guardant Health (GH) shares have slid following news that Principal Financial Group Inc. reduced its stake by 32.8% and corporate insiders, including CMO Terilyn J. Monroe and CTO Darya Chudova, sold approximately 434,627 shares worth $45.6 million. Despite these sales, institutional ownership remains high at about 92.6%, and insiders still hold around 6.10% of the company. The stock is currently trading around $107.58, close to the Street's average target of $106.86, while Google Trends shows a significant increase in searches for "guardant health."
Guardant Health ($GH) Stake Decreased by Key Shareholder
Guardant Health's stock experienced volatility after reports revealed key insiders and a major shareholder reduced their holdings. While insiders often sell shares for personal reasons like tax obligations or diversification, such significant sales can prompt investor scrutiny. Investors are advised to balance these insider transactions with the company's strong revenue growth and market potential in the precision oncology sector.
Guardant Health, Inc. $GH Shares Sold by Principal Financial Group Inc.
Principal Financial Group Inc. reduced its stake in Guardant Health (NASDAQ:GH) by 32.8% in Q3, selling 86,006 shares and now owning 176,516 shares worth $11.03 million. Despite significant insider selling over the past 90 days, institutional investors collectively own 92.6% of the company. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $106.86, while the stock currently trades around $107.58.
Guardant Health Inc (GH) Trading Down 4.5% on Feb 11
Guardant Health Inc (GH) experienced a 4.50% drop in mid-day trading on February 11, reaching an intraday low of $100.27 before settling at $100.30. Wall Street analysts provide an average one-year price target of $121.52, suggesting a 21.16% upside, and their consensus recommendation indicates an "Outperform" status. However, GuruFocus estimates the fair value (GF Value) at $64.76, implying a potential downside of 35.43%.
Guardant Health (GH) Is Down 8.3% After Landmark ctDNA Study in Stage III Colon Cancer
Guardant Health's stock fell 8.3% despite a positive study in the Journal of Clinical Oncology showing its Guardant Reveal blood test more accurately predicts recurrence in stage III colon cancer. The study, conducted with Mayo Clinic and The Alliance for Clinical Trials in Oncology, suggests ctDNA testing could improve postoperative management. While bolstering Guardant Health's investment narrative, core risks around profitability and valuation persist, with the stock trading potentially 32% above fair value according to some estimates.
Minimal Residual Disease Testing Market Poised for Rapid Growth
The global Minimal Residual Disease (MRD) Testing Market is projected to grow at a CAGR of 12.5% during 2024-2031, driven by advancements in precision oncology. This market focuses on detecting low levels of cancer cells post-treatment, especially in hematologic malignancies, utilizing technologies like PCR, next-generation sequencing, and flow cytometry. Key players such as Adaptive Biotechnologies Corp. and Guardant Health are contributing to innovations and partnerships that enhance diagnostic precision and clinical utility.
Assessing Guardant Health (GH) Valuation After New Colon Cancer ctDNA Study Publication
Guardant Health (GH) is in focus after publishing a significant study on its Guardant Reveal blood test for resected stage III colon cancer, showing it identifies patients with higher recurrence risk. While the stock has seen strong returns over the past year, it has experienced recent pullbacks. The article discusses two valuation perspectives: one narrative that deems GH 16% undervalued at $121.19 per share due to growth and AI integration, and another that highlights its high P/S ratio compared to industry averages despite attractive cash flow projections.
IQ EQ FUND MANAGEMENT IRELAND Ltd Lowers Position in Guardant Health, Inc. $GH
IQ EQ FUND MANAGEMENT IRELAND Ltd significantly reduced its stake in Guardant Health, Inc. by 66.8% in Q3, selling 30,254 shares and retaining 15,070 shares valued at approximately $942,000. Despite this reduction, institutional investors collectively own 92.60% of the company's stock, with several other major funds increasing their holdings. Analysts maintain a "Moderate Buy" rating with an average price target of $106.86, even as company insiders have been net sellers in recent months.
Guardant Reveal Study Spurs Fresh Look At Guardant Health Valuation Risks
Guardant Health's Guardant Reveal liquid biopsy test showed promising results in a landmark study for detecting minimal residual disease in stage III colon cancer, more accurately predicting recurrence and survival. This development could significantly impact clinical practice, reimbursement, and adoption of liquid biopsies in oncology. Despite the positive clinical data, Guardant Health remains loss-making with negative shareholder equity, posing a risk for investors.
New York State Common Retirement Fund Has $4.77 Million Stake in Guardant Health, Inc. $GH
The New York State Common Retirement Fund decreased its stake in Guardant Health, Inc. (NASDAQ:GH) by 27.2% in the third quarter, reducing its holding to 76,283 shares valued at approximately $4.77 million. Despite recent insider selling totaling over $45 million, analysts generally maintain a "Moderate Buy" rating for Guardant Health with a consensus target price of $106.86. Guardant Health specializes in blood-based cancer diagnostics using non-invasive tests and its stock currently trades near its 1-year high.
Guardant Reveal Study Spurs Fresh Look At Guardant Health Valuation Risks
A new study on Guardant Health's Guardant Reveal liquid biopsy test for stage III colon cancer, published in the Journal of Clinical Oncology, shows it more accurately predicts recurrence and survival than traditional methods. This could lead to changes in post-surgical monitoring, reimbursement, and adoption for cancer detection. Despite the positive clinical data, Guardant Health remains loss-making with negative shareholder equity.
Precision oncology firm Guardant lines up four investor talks
Guardant Health (Nasdaq: GH), a precision oncology company, announced its participation in four upcoming investor conferences between February 10th and March 11th, 2026. The company will be present at the BTIG MedTech Conference, TD Cowen Health Care Conference, Leerink Partners Global Health Conference, and Barclays Global Healthcare Conference, engaging in 1x1 meetings and fireside chats. Live and archived webcasts of these sessions will be available on the "Investors" section of Guardant Health's website.
Guardant Health to Participate in Upcoming Investor Conferences - February 3, 2026
Guardant Health, a leading precision oncology company, announced its participation in four upcoming investor conferences in February and March 2026. The company will host 1x1 meetings and fireside chats at the BTIG 13th Annual MedTech, TD Cowen 46th Annual Health Care, Leerink Partners Global Health, and Barclays 28th Annual Global Healthcare Conferences. Live and archived webcasts of these sessions will be available on Guardant Health's investor relations website.
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (Nasdaq: GH) announced its participation in four upcoming investor conferences: the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, TD Cowen 46th Annual Health Care Conference, Leerink Partners Global Health Conference, and Barclays 28th Annual Global Healthcare Conference. The company will host 1x1 meetings and participate in fireside chats, with webcasts of sessions available on its investor relations website. Guardant Health is a precision oncology company focused on cancer detection and treatment.
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, a precision oncology company, announced its participation in several upcoming investor conferences in February and March 2026. The company will be present at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, TD Cowen 46th Annual Health Care Conference, Leerink Partners Global Health Conference, and Barclays 28th Annual Global Healthcare Conference. Interested parties can access webcasts of these sessions on Guardant Health's investor relations website.
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a precision oncology company, announced its participation in several upcoming investor conferences. The company will be hosting 1x1 meetings at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, and conducting fireside chats at the TD Cowen 46th Annual Health Care Conference, Leerink Partners Global Health Conference, and Barclays 28th Annual Global Healthcare Conference. Webcasts of these sessions will be available on the investor section of Guardant Health's website.
Guardant Health guides Q4 and FY25 revenue above consensus
Guardant Health (GH) announced its preliminary revenue figures for the fourth quarter of 2024 and provided guidance for its full-year 2025 revenue. Both the Q4 actuals and the FY25 projections are anticipated to exceed current consensus estimates, suggesting a positive outlook for the company's financial performance.
Guardant Health CtDNA Study Reshapes Colon Cancer Care And Investor Focus
Guardant Health's new study on its ctDNA blood test for stage III colon cancer shows improved prediction of recurrence and survival, potentially changing postoperative care and investor sentiment. The company's stock has seen significant returns reflecting growing interest in its cancer diagnostics role. While the study strengthens clinical validation, investors are cautioned to monitor how these findings translate into real-world adoption, reimbursement policies, and market competition.
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
A new study published in the Journal of Clinical Oncology, conducted by Guardant Health, Mayo Clinic, and the Alliance for Clinical Trials in Oncology, demonstrates that the Guardant Reveal blood test more accurately predicts recurrence and overall survival in stage III colon cancer patients after surgery compared to standard staging methods. The test identifies patients at a significantly higher risk of disease recurrence, even those with smaller tumors, supporting the routine integration of tissue-free ctDNA testing to personalize treatment and surveillance decisions. These findings highlight the potential for Guardant Reveal to refine risk assessment beyond traditional TNM staging and guide adjuvant treatment.
Blood test flags colon cancer patients most likely to see disease return
A new study published in the Journal of Clinical Oncology shows that Guardant Health's (NASDAQ: GH) Reveal blood test can more accurately predict the risk of recurrence and overall survival in Stage III colon cancer patients after surgery. The test identifies circulating tumor DNA (ctDNA), with higher levels indicating a significantly increased risk of disease return. These findings support integrating ctDNA testing into routine postoperative care to better tailor treatment and surveillance strategies.
A Look At Guardant Health (GH) Valuation After Strong Recent Shareholder Returns
Guardant Health (GH) has seen significant share price appreciation, with a 1-year return of 142.7%. While a popular narrative suggests the company is modestly undervalued at $121.19 per share, its current P/S ratio of 16.3x is much higher than the US Healthcare average, indicating rich market expectations. Investors are encouraged to consider a deeper dive into the company's financials and risks, or explore other investment ideas within the healthcare sector.
Knights of Columbus Asset Advisors LLC Takes Position in Guardant Health, Inc. $GH
Knights of Columbus Asset Advisors LLC has acquired a new stake in Guardant Health, Inc. (NASDAQ:GH), purchasing 24,876 shares valued at approximately $1.55 million. This move contributes to institutional investors owning a significant 92.6% of the company, while analysts maintain a "Moderate Buy" consensus with an average price target of $106.86. However, substantial insider selling has occurred, with CEO Helmy Eltoukhy selling over $9.4 million in shares and other insiders selling a total of $46.6 million in the past three months.
